AnnJi Pharmaceutical Co., Ltd. (TPEx: 7754), a clinical‑stage drug development company focused on innovative small molecules, announced that it is proceeding with the U.S. portion of its pivotal Phase 3 ROMA‑KD trial of AJ201 (rosolutamide) in patients with spinal and bulbar muscular atrophy (SBMA, or Kennedy’s disease) — a progressive, inherited neuromuscular disease with no FDA‑approved treatment. Following submission of the Phase 3 protocol to the U.S. FDA under AnnJi’s active Investigational New Drug (IND) application, the company will begin U.S. site activation for the global registrational study. AJ201 is described as the only known investigational therapy for SBMA in Phase 3 development worldwide.
Trial Initiation & Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | U.S. FDA (Phase 3 protocol submitted under active IND) |
| Milestone | Advancement into pivotal Phase 3; U.S. site activation underway |
| Product | AJ201 (rosolutamide; also known as JM17), investigational oral small molecule |
| Indication | Spinal and bulbar muscular atrophy (SBMA / Kennedy’s disease) |
| Regulatory Designations | Fast Track Designation (FDA); Orphan Drug Designation (FDA and EMA) |
| Next Steps | Coordinate global site activation in line with development and partnering strategy |
Drug Profile & Mechanism of Action
- Molecule: Investigational oral small molecule with a potential first‑in‑class mechanism for SBMA.
- Primary Target: Promotes clearance of the pathogenic mutant androgen receptor (mAR) protein, the driver of motor neuron and muscle degeneration in SBMA.
- Stress‑Response Activation: Activates cellular defense pathways including Nrf1, Nrf2 and HSF1, supporting antioxidant defense, protein quality control and stress response.
- Therapeutic Concept: Through these complementary mechanisms, AJ201 is being developed as a potential disease‑modifying therapy rather than symptom management alone.
Clinical Development – Phase 3 ROMA‑KD Trial
| Design Element | Detail |
|---|---|
| Study Type | Global, multicenter, randomized, double‑blind, placebo‑controlled |
| Population | Ambulatory individuals with symptomatic SBMA |
| Expected Enrollment | Approximately 200 patients globally, with the United States as a key region |
| Objective | Evaluate efficacy and safety of AJ201; intended to support potential global regulatory submissions |
| Phase 2 Basis | Builds on encouraging results from the completed Phase 2 study announced in May 2025 and subsequent interactions with regulatory authorities (specific efficacy data not disclosed in this release) |
“For people living with SBMA, the disease is felt in everyday moments: a staircase that becomes harder to climb, a meal that becomes harder to swallow, a voice that becomes harder to use,” said Dr. Wendy Huang, Chairperson and CEO of AnnJi. “It affects whole families, often across generations, and there is still no FDA‑approved treatment. Advancing AJ201 into Phase 3 brings us one step closer to potentially changing that.”
Market Impact & Outlook
- Unmet Medical Need: SBMA is a rare, X‑linked inherited neuromuscular disorder caused by a CAG repeat expansion in the androgen receptor gene. There is currently no FDA‑approved treatment, and the disease is believed to be substantially underdiagnosed — often mistaken for ALS — with an approved therapy likely to catalyze genetic testing and diagnosis rates.
- Exclusive Late‑Stage Position: As the only known investigational SBMA therapy in Phase 3 worldwide, AJ201 holds a potential first‑mover advantage in an indication with no direct late‑stage competition disclosed.
- Regulatory Tailwinds: Fast Track Designation enables closer FDA interaction and expedited review pathways, while dual Orphan Drug Designations (U.S. and EU) provide market‑exclusivity incentives and support global commercialization strategy.
- Patient‑Centered Infrastructure: AnnJi has established its SBMA Patient and Care Partner Advisory Council, first announced with the Kennedy’s Disease Association (KDA) at the 2026 KDA International Patient and Scientific Conference — a structured, two‑way forum informing study design and patient‑facing materials, operating independently of trial enrollment.
- Global Readiness: Site activation will be coordinated across regions, positioning the ROMA‑KD data package to support global regulatory submissions and future partnering opportunities.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the timing, conduct and potential outcomes of the Phase 3 ROMA‑KD trial, site activation and enrollment, the regulatory pathway for AJ201, and AnnJi’s development and partnering plans. Actual results may differ materially due to clinical, regulatory, manufacturing, partnering, financing and operational risks. AJ201 is an investigational product and has not been approved by any regulatory authority for any indication. Additional risk information is available in AnnJi’s disclosures filed with the Taipei Exchange (MOPS).-Fineline Info & Tech
